Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-26

In their R&D day; which turns out to be complete fantasy for just about everything, they said TGA provisional approval for CY 2024 - and that it was a key strategic outlook for them.

You have to remember that the TGA have not given them the green light on progressing the Provisional Approval application before the 008 study, which gives insight into the TGA's viewpoint that iPPS doesn't confer any benefit to OA sufferers on pain over and above NSAIDS, because if they thought it did, we'd be progressing the application now.

Pumpers wont tell you that, however.

2026 - first revenue - if lucky.